<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01726322</url>
  </required_header>
  <id_info>
    <org_study_id>ICORG 10-16</org_study_id>
    <nct_id>NCT01726322</nct_id>
  </id_info>
  <brief_title>Anti-Mullerian Hormone Study. ICORG 10-16, V2</brief_title>
  <official_title>A Study to Determine Alteration of Anti-mullerian Hormone (AMH) Concentrations in Premenopausal Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      Primary Objective :

      To determine whether pre-treatment levels of anti-mullerian hormone predicts ovarian
      follicular reserve post adjuvant or neoadjuvant chemotherapy for breast cancer and
      chemotherapy induced amenorrhea (CIA).

      Secondary Objective

        -  To evaluate the comparative ovarian toxicity of differing neo-adjuvant/ adjuvant
           chemotherapy regimens.

        -  To assess the correlation between CIA and depletion of ovarian follicular reserve.

        -  To partly externally validate preceding studies of anti-mullerian hormone levels in
           patients receiving neo-adjuvant/ adjuvant chemotherapy for breast cancer.

        -  To determine the efficacy of GNRH agonists in preservation of ovarian follicles in
           premenopausal women treated with adjuvant or neo-adjuvant chemotherapy for breast
           cancer. Administration of GNRH agonists is dependent on the treating oncologist's
           judgment of the patient's case and practices and is not to be influenced by study
           participation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type of Study: Translational Study

      Sample Type: A 10mL blood sample will be collected in red vacutainer tubes (no anticoagulant,
      no gel) from each patient at the designated time points +/- 7days. Blood should preferably be
      collected in the follicular phase of the menstrual cycle.

      Time of Sample procurement:

        -  1st Sample: Pre-Chemotherapy (â‰¤ 14 days pre-treatment)

        -  2nd Sample: e.g. before cycle 3, if undergoing a 4 cycle regimen or before cycle 4 in a
           6 cycle regimen. (If the chemotherapy regimen changes following the commencement of
           chemotherapy &amp;/or after surgery, then blood samples will be taken at the time points
           determined by the original plan i.e. if a patient was to have 6 cycles of chemotherapy
           and this was then changed to 4 cycles samples will be taken before cycle 4)

        -  3rd sample: 3 weeks following the last dose of chemotherapy

        -  4th sample: 3 months following the last dose of chemotherapy

        -  5th sample: 6 months following the last dose of chemotherapy

        -  6th sample: 1 year following the last dose of chemotherapy

        -  7th sample: 2 years following the last dose of chemotherapy

        -  8th sample: 3 years following the last dose of chemotherapy

      Patient's menstrual status including the commencement date of last menstrual period or the
      use of Intra Uterine Devices (IUD) and FSH, LH and E2 levels will be documented on the
      Baseline Assessment CRF.

      FSH, LH and E2 levels will also be measured at each time point and documented on the
      Follow-up Assessment CRF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of AMH levels from before starting chemotherapy to predefined intervals concluding at 3 years post completion of chemotherapy</measure>
    <time_frame>AMH levels will be taken at specified intervals until 3 years post chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of chemotherapy induced amenorrhea in patients treated with and without GNRH agonists.</measure>
    <time_frame>up to 3 years post chemotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Premenopausal Breast Cancer</condition>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Premenopausal breast cancer patients who are to receive chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented histological diagnosis of invasive breast cancer

          2. Patient due to be treated with chemotherapy (neoadjuvant or adjuvant)[Patients treated
             with GNRH agonist or adjuvant Herceptin or participating in other clinical trials are
             also eligible]

          3. Female patients aged between 18 and 42 years

          4. Premenopausal status as defined by a hormone profile (FSH, LH, E2 within the
             pre-menopausal range as defined by local lab).

             OR

             -The last menstrual period had to be within 180 days

             OR

             -An IUD is used for contraception

          5. Karnofsky score greater or equal to 70

          6. Ability to provide written informed consent

        Exclusion Criteria:

          1. Patients with hypothalamic/pituitary disorder

          2. History of ovarian tumour

          3. Current pregnancy (pregnancy test as per hospital standard prior to treatment)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beacon Hospital</name>
      <address>
        <city>Bracken Rd, Sandyford Industrial Estate</city>
        <state>Dublin 18</state>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Westrup</last_name>
      <phone>01 293 6600</phone>
    </contact>
    <contact_backup>
      <last_name>Dr Jennifer Westrup</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Hospital</name>
      <address>
        <city>Drogheda</city>
        <state>Louth</state>
        <zip>Co</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Hennessy, Dr</last_name>
      <phone>01-8092010</phone>
    </contact>
    <investigator>
      <last_name>Bryan Hennessy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>021-4542807</phone>
    </contact>
    <investigator>
      <last_name>Brian Bird, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>021-4546400</phone>
    </contact>
    <investigator>
      <last_name>Seamus O'Reilly, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-8092373</phone>
    </contact>
    <investigator>
      <last_name>Oscar Breathnach, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-4103000</phone>
    </contact>
    <investigator>
      <last_name>John Kennedy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01-2214000</phone>
    </contact>
    <investigator>
      <last_name>Janice Walshe, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Adelaide &amp; Meath Hospital, Dublin, Incorporating the National Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>01- 414 2000</phone>
    </contact>
    <investigator>
      <last_name>Janice Walshe, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>091-544805</phone>
    </contact>
    <investigator>
      <last_name>Maccon Keane, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sligo General Hospital</name>
      <address>
        <city>Sligo</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>071- 9171111</phone>
    </contact>
    <investigator>
      <last_name>Michael Martin, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterford Regional Hospital</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>051-848000</phone>
    </contact>
    <investigator>
      <last_name>Miriam O'Connor, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2012</study_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

